Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5674047 | 0.78 | KDM4E (0.37) | KDM4EMAPTNPSR1RECQLSMN1; SMN2 | |
| SCHEMBL31627684 | 0.78 | KDM4E (0.37) | KDM4EMAPTNPSR1RECQLSMN1; SMN2 | |
| SCHEMBL8285130 | 0.77 | LMNA (0.47) | KDM4EMAPTNPSR1RECQLSMN1; SMN2 | |
| SCHEMBL29954850 | 0.77 | LMNA (0.47) | KDM4EMAPTNPSR1RECQLSMN1; SMN2 | |
| SCHEMBL12640263 | 0.75 | ALDH1A1 (0.32) | ALDH1A1 | |
| SCHEMBL10951849 | 0.73 | LMNA (0.34) | KDM4EMAPTNPSR1RECQLSMN1; SMN2 | |
| SCHEMBL4217754 | 0.73 | KDM4E (0.37) | KDM4EMAPTNPSR1RECQLLMNA | |
| SCHEMBL13431148 | 0.72 | CA1 (0.46) | KDM4EMAPTNPSR1RECQLSMN1; SMN2 | |
| SCHEMBL114532 | 0.70 | MAPT (0.40) | KDM4EMAPTNPSR1RECQLSMN1; SMN2 | |
| SCHEMBL11986397 | 0.68 | FLT3 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110160232-A1 | CERTAIN CHEMICAL ENTITIES AND THERAPEUTIC USES THEREOF | INTELLIKINE LLC | 2011-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160232-A1 | CERTAIN CHEMICAL ENTITIES AND THERAPEUTIC USES THEREOF | PIK3CA, PIK3C3, PRKACA | KDM4E 3724/4885MAPT 1095/4885NPSR1 4180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.